Next Article in Journal
Drug-Induced Subacute Cutaneous Lupus Erythematosus Associated with Nab-Paclitaxel Therapy
Previous Article in Journal
Oncofertility in Canada: An Overview of Canadian Practice and Suggested Action Plan
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on as a courtesy and upon agreement with Multimed Inc..

Benefits, Issues, and Recommendations for Personalized Medicine in Oncology in Canada

Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, AB, Canada
Department of Pathology, Division of Molecular Diagnostics, The University Health Network, Toronto, ON, Canada
Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, QC, Canada
Department of Medicine, University of British Columbia, BC Cancer Agency, Vancouver, BC, Canada
Medical Oncology, Vancouver General Hospital and the University of British Columbia, and Systemic Therapy, BC Cancer Agency, Vancouver, BC, Canada
Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, and Mount Sinai Hospital, Toronto, ON
Centre of Excellence in Personalised Medicine, Montreal, QC, Canada
Intelligent Improvement Consultants, Inc., Toronto, ON, Canada
lllawarra Health Medical Research Institute, University of Wollongong,Wollongong, NSW, Australia
Author to whom correspondence should be addressed.
Curr. Oncol. 2013, 20(5), 475-483;
Received: 2 July 2013 / Revised: 3 August 2013 / Accepted: 5 September 2013 / Published: 1 October 2013
The burden of cancer for Canadian citizens and society is large. New technologies have the potential to increase the use of genetic information in clinical decision-making, furthering prevention, surveillance, and safer, more effective drug therapies for cancer patients. Personalized medicine can have different meanings to different people. The context for personalized medicine in the present paper is genetic testing, which offers the promise of refining treatment decisions for those diagnosed with chronic and life-threatening illnesses. Personalized medicine and genetic characterization of tumours can also give direction to the development of novel drugs. Genetic testing will increasingly become an essential part of clinical decision-making. In Canada, provinces are responsible for health care, and most have unique policies and programs in place to address cancer control. The result is inconsistency in access to and delivery of therapies and other interventions, beyond the differences expected because of demographic factors and clinical education. Inconsistencies arising from differences in resources, policy, and application of evidence-informed personalized cancer medicine exacerbate patient access to appropriate testing and quality care. Geographic variations in cancer incidence and mortality rates in Canada—with the Atlantic provinces and Quebec having higher rates, and British Columbia having the lowest rates—are well documented. Our purpose here is to provide an understanding of current and future applications of personalized medicine in oncology, to highlight the benefits of personalized medicine for patients, and to describe issues and opportunities for improvement in the coordination of personalized medicine in Canada. Efficient and more rapid adoption of personalized medicine in oncology in Canada could help over-come those issues and improve cancer prevention and care. That taks mignth benefit from the creation of a National Genetics Advisory Panel that would review research and provide recommendations on tests for funding or reimbursement, guidelines, service delivery models, laboratory quality assurance, education, and communication. More has to be known about the current state of personalized cancer medicine in Canada, and strategies have to be developed to inform and improve understanding and appropriate coordination and delivery. Our hope is that the perspectives emphasized in this paper will stimulate discussion and further research to create a more informed response.
Keywords: personalized medicine; genetic testing; practice; quality; patient care; policy; guidelines personalized medicine; genetic testing; practice; quality; patient care; policy; guidelines
MDPI and ACS Style

Butts, C.; Kamel–Reid, S.; Batist, G.; Chia, S.; Blanke, C.; Moore, M.; Sawyer, M.B.; Desjardins, C.; Dubois, A.; Pun, J.; Bonter, K.; Ashbury, F.D. Benefits, Issues, and Recommendations for Personalized Medicine in Oncology in Canada. Curr. Oncol. 2013, 20, 475-483.

AMA Style

Butts C, Kamel–Reid S, Batist G, Chia S, Blanke C, Moore M, Sawyer MB, Desjardins C, Dubois A, Pun J, Bonter K, Ashbury FD. Benefits, Issues, and Recommendations for Personalized Medicine in Oncology in Canada. Current Oncology. 2013; 20(5):475-483.

Chicago/Turabian Style

Butts, C., S. Kamel–Reid, G. Batist, S. Chia, C. Blanke, M. Moore, M.B. Sawyer, C. Desjardins, A. Dubois, J. Pun, K. Bonter, and F.D. Ashbury. 2013. "Benefits, Issues, and Recommendations for Personalized Medicine in Oncology in Canada" Current Oncology 20, no. 5: 475-483.

Find Other Styles

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop